Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche anti-TIGIT hope turns to Tecentriq

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 30, 2023 5:23pm

149 Views

Post# 35563956

RE:RE:RE:RE:RE:Roche anti-TIGIT hope turns to Tecentriq

So ... for those who got lost on the way here, this again bring up the subject of triplet therapy involving ONCY's pelareorep. Therfore, how we got here is not in the same way to where we are going.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing